Evidence map›Paper›PMID 42398997›Full record

ArticleBMJ open2026

Understanding the impact of the follow-up period on the association between excess body weight, and cardiovascular events and mortality: a prospective cohort study of the UK Biobank.

Jufen Zhang, Henry Oluwasefunmi Savage, Jason N Dungu, Rudolph Schutte, Barbara Pierscionek

Abstract read
In one paragraph

Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jufen ZhangClinical Trials Unit, School of Medicine, Faculty of Health, Medicine and Social Care, Anglia Ruskin University, Chelmsford, UK jufen.zhang@aru.ac.uk.ORCID http://orcid.org/0000-0003-2704-6212
Henry Oluwasefunmi SavageCentre for Biomedicine and Health Innovation, Faculty of Health, Medicine and Social Care, Anglia Ruskin University, Chelmsford, UK.ORCID http://orcid.org/0000-0001-8574-6511
Jason N DunguCentre for Biomedicine and Health Innovation, Faculty of Health, Medicine and Social Care, Anglia Ruskin University, Chelmsford, UK.
Rudolph SchutteCentre for Biomedicine and Health Innovation, Faculty of Health, Medicine and Social Care, Anglia Ruskin University, Chelmsford, UK.
Barbara PierscionekCentre for Biomedicine and Health Innovation, Faculty of Health, Medicine and Social Care, Anglia Ruskin University, Chelmsford, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveStudies have examined the association between excess body weight and risk of cardiovascular (CV) outcomes in the general population. However, the impact of the follow-up period of excess body weight on the association between excess weight and CV outcomes is less investigated. We sought to investigate this using the UK Biobank data. STUDY

designPopulation-based prospective cohort study.

settingThe UK.

participantsAdults aged between 40 and 69 years were recruited between 2006 and 2010. The study included 469 162 participants; the median (IQR) age was 57 (50-63) years, and 56.3% of the participants were female. EXPOSURES: Body mass index, age, gender, ethnicity, education, smoking status (never, previous and current), alcohol status (never, previous and current), systolic blood pressure, sleep duration, walking pace, overall health rating (excellent, good, fair and poor), dietary patterns (such as red and processed meat consumption, and intake of fish, fruit, poultry and vegetables) and self-reported medical history (such as diabetes, chest pain/discomfort and falls). OUTCOMES: CV outcomes, including CV events such as cerebrovascular disease, ischaemic heart disease, heart failure and CV death.

resultsOf the 469 162 participants without CV disease at baseline, 56.3% were female. The mean age was 57 (SD: 9.6) years. During the median follow-up of 13.7 (IQR: 12.9-14.4) years, 27 305 participants developed a CV outcome, including 6698 who had a CV death. Overall, the strength of association between obesity and CV outcomes increased gradually as the follow-up period increased compared with normal weight. A significant association between obesity and the first CV event was observed after 4 years follow-up period (HR (95% CI) 1.14 (1.02 to 1.26)). The association of obesity with CV death was found after 10 years of follow-up, and there was an increasing strength of the association between 10 years (1.11 (1.01 to 1.22)) and 15 years (1.21 (1.13 to 1.29)) follow-up periods. No association was found between being overweight and CV death at any follow-up. Both overweight and obesity in men were associated with CV death observed before 8 years, while obese women were found to be associated with CV events and CV death after 8 years follow-up period.

conclusionsThis large observation study shows that obesity could lead to CV death as early as 10 years follow-up period, while individuals who were obese were more likely to have their first CV event after 4 years follow-up. No association between being overweight and CV death was observed in any follow-up time. Further studies are needed to evaluate the impact of the follow-up period on associations between overweight/obesity and CV outcomes. Screening or early intervention for obesity can be highly valuable for preventing and managing CV outcomes in a primary care setting.

Indexed as

Cardiovascular DiseasesObesityOverweightAdultAgedBody Mass IndexFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesRisk FactorsUK BiobankUnited KingdomBody Mass IndexCardiovascular DiseaseDeathObesityObservational Study

Identifiers

PMID42398997
PMCPMC13343087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.